FIG 2.

VP2 is a target for SUMOylation. (a) AAV2 vectors lacking either VP2, VP1, or VP1/2 were produced and purified by iodixanol gradient centrifugation. Vectors were analyzed by Western blotting using an anti-SUMO1 or the VP-specific antibody B1. (b) Analysis of AAV2 vectors carrying an N-terminally modified VP2. Vectors were produced as described for panel a. Lane 4 shows AAV vectors carrying a VP2 N-terminally fused GFP, and in lane 5 the HA tag is fused to the N terminus of VP2. (c) Detection of VP using a polyclonal antibody.